Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer. by Rega, Daniela et al.
RESEARCH ARTICLE
Evaluation of Tumor Response after Short-
Course Radiotherapy and Delayed Surgery
for Rectal Cancer
Daniela Rega1*, Biagio Pecori2, Dario Scala1, Antonio Avallone3, Ugo Pace1,
Antonella Petrillo4, Luigi Aloj5, Fabiana Tatangelo6, Paolo Delrio1
1 Colorectal Surgical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori–“Fondazione Giovanni
Pascale” IRCCS, Naples, Italy, 2 Division of Radiotherapy, Department of Diagnostic Imaging, Radiant and
Metabolic Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori–“Fondazione Giovanni Pascale”
IRCCS, Naples, Italy, 3 Division of Gastrointestinal Medical Oncology, Istituto Nazionale per lo Studio e la
Cura dei Tumori–“Fondazione Giovanni Pascale” IRCCS, Naples, Italy, 4 Division of Radiology, Department
of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale per lo Studio e la Cura dei
Tumori–“Fondazione Giovanni Pascale” IRCCS, Naples, Italy, 5 Nuclear Medicine Unit, Istituto Nazionale
per lo Studio e la Cura dei Tumori–“Fondazione Giovanni Pascale” IRCCS, Naples, Italy, 6 Pathology Unit,
Istituto Nazionale per lo Studio e la Cura dei Tumori–“Fondazione Giovanni Pascale” IRCCS, Naples, Italy
* daniela.rega@gmail.com
Abstract
Purpose
Neoadjuvant therapy is able to reduce local recurrence in rectal cancer. Immediate surgery
after short course radiotherapy allows only for minimal downstaging. We investigated the
effect of delayed surgery after short-course radiotherapy at different time intervals before
surgery, in patients affected by rectal cancer.
Methods
From January 2003 to December 2013 sixty-seven patients with the following characteris-
tics have been selected: clinical (c) stage T3N0 12 cm from the anal verge and with cir-
cumferential resection margin > 5 mm (by magnetic resonance imaging); cT2, any N, < 5
cm from anal verge; and patients facing tumors with enlarged nodes and/or CRM+ve who
resulted unfit for chemo-radiation, were also included. Patients underwent preoperative
short-course radiotherapy with different interval to surgery were divided in three groups: A
(within 6 weeks), B (between 6 and 8 weeks) and C (after more than 8 weeks). Hystopatolgi-
cal response to radiotherapy was measured by Mandard’s modified tumor regression grade
(TRG).
Results
All patients completed the scheduled treatment. Sixty-six patients underwent surgery. Fifty-
three of which (80.3%) received a sphincter saving procedure. Downstaging occurred in 41
cases (62.1%). The analysis of subgroups showed an increasing prevalence of TRG 1–2
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prolonging the interval to surgery (group A—16.7%, group B—36.8% and 54.3% in group
C; p value 0.023).
Conclusions
Preoperative short-course radiotherapy is able to downstage rectal cancer if surgery is
delayed. A higher rate of TRG 1–2 can be obtained if interval to surgery is prolonged to
more than 8 weeks.
Introduction
Preoperative long course radiotherapy has been shown to be effective in downsizing locally
advanced rectal tumors [1–3]. Long-course chemo-radiation has been extensively applied and
encouraging results derive from this approach in terms of local control with a high rate of
tumor regression up to a significant rate of complete response. Short-course radiotherapy
(SCR) has been used with a different goal, i.e. “sterilizing” the irradiated area immediately
before surgery without any expected on the tumor’s stage and size. This is mainly due to the
short overall treatment time (OTT) in patients operated on in the week following the end of
the radiotherapy. It is known that delaying surgery after chemo-radiation produces a signifi-
cant rate of tumor regression [4–8]. Therefore the increase of the OTT (by prolonging the
interval between radiation and surgery) could raise the rate of tumor regression and induce a
higher rate of complete response even in patients treated with SCR [9–11]. There aren’t many
data on the effect on tumor regression due to a prolonged interval after SCR in locally advanced
rectal cancer: Pach et al and Stockholm III trial don’t produce significant different with delayed
surgery [12]. Tumor regression grade (TRG) is a powerful indicator of response to a neoadju-
vant treatment in rectal cancer and can measure the effectiveness of radiation therapy. The aim
of this study was to evaluate the TRG as indicator of response to SCR followed by a progressive
prolonged interval prior to surgery in patients with middle and distal rectal adenocarcinoma.
Material and Methods
A dedicated database with all information on 649 rectal cancer patients assessed and treated at
our Istitution was retrospectively analysed. Since January 2003 to December 2013 sixty–seven
consecutive patients with rectal cancer cT3N0 12 cm from the anal verge and with circum-
ferential resection margin (CRM)> 5 mm, evaluated by magnetic resonance imaging (MRI),
1) cT2 any N< 5 cm from anal verge, and 2) tumors with N+ that are unfit for long course che-
moradiation, have been treated with preoperative SCR. All patients were discussed into a mul-
tidisciplinary case conference: staging and medical comorbidities were considered. In our
series we used preoperative short-course radiation as an alternative to CRT in elderly patients
or for patients unfit for preoperative chemotherapy due to severe comorbidities (ant T, any N,
any CRM). The Karnofsky index was also used to score the patient general conditions and only
patients with KPS 70 were considered eligible for long chemoradiation and here defined as
fit for combined neoadjuvant therapy. Surgery alone is performed in early rectal cancer cT1
cN0 cCRM< 5 mm.
During the study period, the interval between the completion of radiation treatment and
surgery was progressively prolonged from one to 10 weeks. The increase was defined into three
different calendar periods, as depicted in Table 1. Beneficial to a simpler analysis, patients were
then divided into three groups: group A (surgery within 6 weeks from SCR), group B (surgery
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between 6 and 8 weeks from SCR) and group C (surgery after more than 8 weeks from SCR).
Patients with rectal cancer underwent a pre-treatment work-up including whole body com-
puter tomography (CT) scan, pelvic MRI and endorectal ultrasound. A positron emission
tomography (PET) scan was also performed in most patients before radiation therapy and
before surgery to monitor response to treatment. All pre-treatment exams were repeated with
the restaging before the planned operation. Downstaging was considered as the reduction of
the pathological stage both for tumor and lymphnodes after neoadjuvant therapy.
Radiotherapy
All patients underwent dose-planning CT in prone position. After an on line CT virtual simu-
lation, CT datasets were transferred to a dedicated treatment planning system through a
DICOM network and an individualized clinical target volume (CTV) was done, including the
gross tumor volume with margins (2–3 cm depending upon tumor position, defined by MRI
imaging), the mesorectum and regional lymph nodes depending upon tumor location. We con-
toured the small bowel, the femoral heads and the bladder as critical organs on all CT slices of
every patient, and we evaluated the relative dose–volume histogram on the treatment planning
console. Three-dimensional plans for 3D radiotherapy were generated for a dual-energy (6 and
20MV x-rays) linear accelerator (Clinac 2100C/D) equipped with multileaf collimators (MLC).
Patients were scheduled using a 3 field arrangement to include the PTV within the 95% isodose
Table 1. Baseline characteristics of the patients grouped according to interval to surgery.
< 6 wk 6–8 wk > 8 wk p
n = 12 (%) n = 19 (%) n = 35 (%)
Gender 0.32*
Male 5 (41.7) 13 (68.4) 23 (65.7)
Female 7 (58.3) 6 (31.6) 12 (34.3)
Age (years) 0.93**
Mean (SD) 69 (12.8) 71 (10.1) 71 (10.7)
Range 31–80 43–85 49–91
Study period < 0.001*
2003–2004 9 (75.0) 1 (5.3) 0 (0)
2005–2008 2 (16.7) 12 (63.2) 4 (11.4)
2009–2013 1 (8.3) 6 (31.6) 31 (88.6)
Stage 0.10*
I—T2N0 1 (8.3) 0 (0) 2 (5.7)
II—T3N0 11 (91.7) 14 (73.7) 20 (57.1)
III—T2-3N1-2 0 (0) 5 (26.3) 13 (37.2)
Distance from a.v. 0.28*
 5 cm 7 (58.3) 9 (47.4) 13 (37.2)
5–8 cm 5 (41.7) 5 (26.3) 11 (31.4)
 8 cm 0 (0) 5 (26.3) 11 (31.4)
Fitness for long course chemoradiation 0.008*
Unfit 4 (33.3) 14 (73.7) 11 (31.4)
Fit 8 (66.7) 5 (26.3) 24 (68.6)
*exact chi-square test
** Kruskal-Wallis non parametric Analysis of variance
doi:10.1371/journal.pone.0160732.t001
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and a dose of 25 Gy in 5 fractions over 1 week was prescribed to the ICRU 62 intersection
point. Adverse effects of RT were scored according to the Radiation Therapy Oncology Group
(RTOG) toxicity criteria [13]. Adverse effects were defined as severe, corresponding to RTOG
grade 3–4, when required hospitalization during the interval between the beginning of RT and
surgery, or within 90 days.
Surgery
Surgical planning was made on the results of restaging. Downsizing and downstaging were
considered as an opportunity to perform sphincter saving surgery in those patients without
sphincter involvement before treatment. Also local excision was considered a possible option
in patients with a significant clinical response assessed by MRI and proctoscopy. The planned
operation was discussed with the patients and a specific informed consent was obtained. A rec-
tal resection with total mesorectal excision and bilateral nerve sparing where possible was the
standard operation. In distal cancers an ultralow anterior resection with coloanal manual anas-
tomosis or, in case of sphincters involvement, an abdomino-perineal resection were performed.
All patients receiving an anastomosis underwent construction of a protecting ileostomy. Com-
plications were classified according to the Clavien Dindo scoring [14].
Pathology
Postsurgical pathology examination provided a macroscopic description of the mesorectum
and of the former tumor-bearing area; at least four paraffin blocks were processed, and an addi-
tional larger area block was embedded. If no tumor was visible, the entire suspicious area was
sliced and embedded. CRM was judged to be involved if the microscopic tumor was< 1mm
from the radial resection margin. The TRG was assessed by the pathologist and scored accord-
ing to a five-point system [15]. Briefly, TRG 1 was a complete tumor regression (regardless of
the presence of acellular mucine lakes), and TRG 2 was a nearly complete tumor regression
with extensive fibrosis; TRG 3 presented a clear evidence of residual cancer cells but with pre-
dominant fibrosis; TRG 4 was a residual of cancer cells outgrowing fibrosis; TRG 5 was the
absence of regressive changes. A major response consisted of TRG 1–2 while a TRG 3–4 was
classified as minor.
Statistics
Baseline comparisons each group were performed by using chi-square test for categorical vari-
ables and Kruskal-Wallis non parametric ANOVA for age. The effect of treatment on out-
comes was assessed by exact Cochrane-Armitage trend test. Multivariate analysis of the effect
of the interval to surgery was performed with a logistic regression model using TRG as
response variable and baseline stage and fitness as potential confounding covariates. TRG was
dichotomized as TRG 1–2 (major pathological response) versus TRG 3–5. Analyses were per-
formed with StatXact and STATA software.
Results
Among the sixty seven patients treated with SCR, 30 (44,8%) with a clinical history of heart
deficiency (relative contraindication to the fluoropirymidines), with liver or kidney deficiency
were excluded from long course chemoradiation. The radiation treatment was completed in all
patients. Adverse effects were registered only in 11 of 67 patients. (16,9%–10 proctitis grade
2–3, 1 enteritis grade 2 in the 2 weeks following SCR). Groups did not differ by age, gender and
distance from a.v. All but one patient, with a critical morbidity who refused the operation, were
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referred for radical surgery. Surgery consisted of a sphincter saving procedure in 53 (80,3%)
patients and a stoma operation (APR, Hartmann) in the remaining 13 (19.7%) cases. A R0
resection was achieved in 65 (98.5%) cases. Among sphincter saving procedures a low anterior
resection was the most (48 patients) performed operation along with a transanal resection in 5
patients. Eighteen (27.7%) patients experienced postoperative complications with a 7.6% of
Clavien-Dindo grade III events. Postoperative death occurred in 4 (6.1%) patients. All deaths
occurred in critically ill patients, unfit for chemoradiation and with a high ASA score. Compli-
cation rate was higher in the group operated on between weeks 6 and 8 (Table 2).
Overall tumor regression grading indicated a poor response (grade 3–4) in 37 of 66 (56.1%)
patients and a good response (grade 1–2) in the remaining 28 of 66 (42.4%)–(Table 3). Patho-
logic tumor downstaging occurred in 53 of 66 (80.3%). Nodal downstaging was detected in 7 of
16 (43.7%) patients deemed N+ve at pre-treatment staging and who underwent to proctect-
omy. Both tumor regression grading and downstaging were re-analysed dividing patients into
subgroups considering the time to surgery. Rate of major patological response (TRG 1–2) sig-
nificantly increased with interval to surgery ranging from 16.7% when the interval was short
(< 6 weeks) to 54.3% when the interval was longer than 8 weeks. No significant difference was
observed for stage, pT and pN, although the latter finding is strongly affected by the small size
(Table 3).
Multivariate analysis showed that, in comparison with an interval to surgery> 8 weeks,
indeed, odds ratio (OR) of response (TRG 1–2) was reduced both when interval was< 6 weeks
(OR 0.11, 95% CI 0.20 to 0. 4) and when surgery occurred 6–8 weeks after SCR (OR 0.54, 95%
CI 0.15 to 1.95). The OR of response was also reduced by stage 3 and unfitness, but neither one
covariate reached statistical significance (Table 4).
The reasons behind patients’ unfitness for long course chemoradiation were significantly
different among the three groups mainly because of a larger rate of unfit patients in the 6 to 8
wk group. In the multivariate analysis unfit patients had a poorer outcome (OR = 0.56) that
was not statistically significant (p = 0.319).
After a median follow up of 24 months, 52 patients are alive: local recurrence occurred in 4
(6.4%) and distant metastases in 3 (4.8%) patients. Six patients died: 3 because of the disease
and 3 for non diseases related causes. Local recurrence occurred in 1 ypT1N0 patient (group B)
treated with local excision, 3 ypN+ve patients (2 group B, 1 group C). One of these last patients
had received the R1 resection. Distant metastases occurred in 1 ypT2N0 patient of group B and
in 2 ypN+ve patients also from (group B). In all patients who had local or systemic relapse the
TRG score was poor (grade 3–4, 1 patient TRG 5).
Discussion
Delaying surgery after SCR induces a significant rate of tumor regression. Complete local
tumor response after preoperative treatment in rectal cancer is considered an important prog-
nostic indicator. In recent years, many efforts have been made aiming to increase response rate
using hypofractionated radiotherapy or long course radiotherapy and concomitant chemother-
apy with more effective drugs and regimens [16–18]. Delayed surgery (four to eight weeks
interval) is usually performed after long-course preoperative chemoradiation in locally
advanced rectal cancer. Delayed surgery allows a downsizing of the tumor and in many cases
also a notable downstaging. This occurs with both radiotherapy doses greater than 40 Gy at a
conventional fractionation and a delay of at least four weeks when there is enough time for
tumor cells to die, thus obtaining a significant mass reduction. In fact Lyon R90-01 trial showed
a significant increase in tumor response considering an interval of six weeks [19].
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Table 2. Compliance of radiotherapy and surgical procedures according to different intervals.
< 6 wk 6–8 wk 8 wk p
n = 12 (%) n = 19 (%) n = 35 (%)
RT Toxicity 3 (25%) 2 (10.5%) 6 (17.1%)
Surgical procedure (n = 66) 0.59*
Sphincter saving 9 (75%) 14 (73.7%) 30 (85.7%)
LAR 9 (75%) 14 (73.7%) 25 (71.4%)
Transanal local resection / / 5 (14.3%)
Stoma operation 3 (25%) 5 (26.3%) 5 (14.3%)
Miles 2 (16.7%) 2 (10.5%) 4 (11.4%)
Hartmann 1 (8.3%) 3 (33.3%) 1 (2.8%)
R0 resection 12 (100%) 19 (100%) 34 (97.1%) > 0.99*
Postoperative complications 4 (33.3%) 7 (36.8%) 7 (20%) 0.10*
Clavien Dindo
grade I 1 4 4
grade II 1 1 1
grade III 1 (8.3%) 2 (22.2%) 2 (5.7%)
Distance from a.v. 0.37*
 5 cm 7 (58.3) 9 (47.4) 13 (37.2)
5–8 cm 5 (41.7) 5 (26.3) 11 (31.4)
 8 cm 0 (0) 5 (26.3) 11 (31.4)
Deaths 1 (8.3%) 1 (5.3%) 2 (5.7%)
*exact chi-square test
doi:10.1371/journal.pone.0160732.t002
Table 3. Observed outcomes by interval to surgery.
< 6 wk 6–8 wk 8 wk p
n = 12 (%) n = 19 (%) n = 35 (%)
TRG 0.023^
1–2 2 (16.7) 7 (36.8) 19 (54.3)
3–5 10 (83.3) 12 (63.2) 16 (45.7)
pT 0.67^
down stage 9 (75.0) 15 (78.9) 29 (82.9)
same or upstage 3 (25.0) 4 (21.1) 6 (17.1)
pN(**) (***) 0.31*
down stage (§) 1/5 (20.0) 6/11 (54.5)
same or upstage (§) 4/5 (80.0) 5/11 (45.5)
Stage 0.87^
down stage 8 (66.7) 10 (52.6) 23 (62.9)
same or upstage 4 (33.3) 9 (47.4) 12 (37.1)
^Exact Cochrane-Armitage trend test
(§) All patients were N0 at baseline
*by Fisher's exact test, group 6–8 wk vs group > 8 wk
**only patients with baseline N>0
*** two N1 patients received local excision
doi:10.1371/journal.pone.0160732.t003
Response to 5x5 Gy RT in Rectal Cancer
PLOS ONE | DOI:10.1371/journal.pone.0160732 August 22, 2016 6 / 10
In patients undergoing classical SCR the overall treatment time (OTT) is never greater than
two weeks, being the patients operated on in the week following the completion of radiother-
apy. Thus the interval between SCR and surgery is too short for a significant tumor regression.
Data from the Dutch trial show a small reduction in size of rectal tumors, possibly due to apo-
ptotic death of intratumoral lymphatic cells; also a reduction of detected lymphnodes is also
observed but no impact on tumor stage and number of metastatic lymphnodes is obtained [9].
Thus it is possible to assume that preoperative SCR does not have an impact on rectal cancer
regression and no downstaging occurs if immediate surgery is performed. In our series, the
median time from completion of SCR to surgery was 61 days (almost 8 weeks), a longer interval
compared with the usual northern european approach. If compared with pre-treatment stag-
ing, ypTNM showed a downstaging in 53 of 66 (80.3%) patients.
The Stockholm III trial has randomized rectal cancer patients to either long-course radio-
therapy (50 Gy), SCR with immediate surgery or SCR with delayed surgery (6–8 weeks “waiting
period”). An interim analysis including 300 patients showed that delaying surgery after SCR is
a feasible approach [20]. Other observational retrospective studies [10, 11, 21, 22] proved that a
significant downstaging with a fair rate of pathologic complete response can be obtained in
selected patients increasing the interval between completion of SCR and surgery.
All these data support the hypothesis that SCR followed by delayed surgery might produce
down-staging or at least down-sizing of rectal cancer with low toxicity. Our results confirm
that SCR is a well tolerated treatment. Protocol norms were strictly adhered to in all treated
patients with a 16.4% of RT related complications. Delayed surgery did not modify the strategy
treatment. An operation could be performed in almost all patients (one patient refused the
operation because of a high morbidity risk). Despite postoperative deaths occurred in 6.1% of
patients it has to be underscored that all the deaths occurred in patients with pretreatment crit-
ical clinical conditions. A major morbidity was reported in five patients (7.6%).
An effective method of “scoring” tumor response is the evaluation of tumor regression
grade. It is reproducible and several scales have been described to better score the relationship
between residual tumor and fibrosis induced by radiation treatment. In our experience TRG is
suitable to verify the effectiveness of neoadjuvant therapy in rectal tumors [23]. Moreover TRG
can help to define possible adjuvant strategies in patients treated into a neoadjuvant setting.
The delayed time to surgery in our series produces interesting results in terms of tumor
regression. Tumor regression grade evaluation showed a significant local response for a treat-
ment that is not normally, i.e. without delayed surgery, expected to induce a regression with a
global response rate of 42.4% for TRG 1–2 and a 56.1% of TRG 3–4. More importantly TRG
1–2 progressively increased with the raise extension of the time interval to surgery from less
Table 4. Multivariate analysis of the effect of the interval to surgery on Tumor Regression Grade
(TRG).
Variable Odds ratio (95% C.I.) p
Interval to surgery 0.022
< 6 wk vs > 8 wk 0.11 (0.20 to 0.64)
6–8 wk vs >8 wk 0.54 (0.15 to 1.95)
Stage 0.095
3 vs 1–2 0.35 (0.10 to 1.20)
Fitness 0.319
Unfit vs Fit 0.56 (0.17 to 1.77)
C.I.: confidence interval
doi:10.1371/journal.pone.0160732.t004
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than 6 weeks to more than 8 weeks, whereas the rate of poor response (TRG 3–4) was inversely
reduced. Tumor regression rate is poor in patients operated any earlier than 8 weeks, but it
raises/it increases if the interval is taken to more than 8 weeks. The prognostic role of the time
interval to interval of surgery was confirmed at multivariate analysis, after adjustment by base-
line stage and fitness (p = 0.022).
Another major issue about SCR is that it is well tolerated, a low toxicity and a good impact
on local control in low risk rectal cancer patients. In our series the local recurrence rate is 6.4%,
and it occurred in patients with tumours at high risk of recurrence that could be better treated
with chemoradiation (N+ve, poor local response). We believe that the optimal surgery offered
in all resected cases contributed to this result. In addition a disease free survival rate close to
77.5% in patients with a median 24 months follow up is an extremely encouraging result and
could confirm that an effective local control (RT + surgery) might concur to provide a long
term survival: a longer follow up is however needed to back up this issue.
Our study is a retrospective analysis of a single institution in which a prospective trial of
delaying surgery after short RT was not planned, but introduced into a therapeutic alghoritm
approved by an institutional board. The progressive increase of the delay from 2 to more than
eight weeks was allowed over the time because of external scientific evidence [19]. With new
evidences [5] that an increased pathologic complete response rate and downstaging occurred
with an RT-surgery interval increased up to 58 days, we progressively raised the interval to
more than 8 weeks. Since 2009 an interval of more than 8 weeks was costantly adopted. Not-
withstanding there was just a minimum overlapping of the study periods among interval
groups. Therefore there is an almost complete confounding that can not be accounted for by a
multivariate analysis. This is of course another limitation of the study.
Despite this matter, this paper offers two crucial pieces of information on the issues
related to the multidisciplinary approach to rectal cancer. Firstly, is that, as already shown in
a different subset of patients with more advanced disease and using chemoradiation [24],
pathologic downstaging is higher when surgery is performed after more than 8 weeks after
the end of neoadjuvant therapy. An interval between 8 and 10 weeks may be ideal to from the
increased time for the tumor to shrink and eventually disappear (complete response) and it is
not long enough to increase the risk of tumor progression. Larger studies in randomized clin-
ical trial should define the optimal interval between SCR and surgery as proposed by Evans
et al [25].
The second issue is related to the feasibility of a preoperative approach to locally advanced
rectal tumor by the SCR alone followed by delayed surgery. A satisfying rate of complete
pathological response can be achieved in selected patients, with a treatment that carries a low
toxicity and is well tolerated by the patients. Moreover, the impact on the routine activity of a
radiation therapy department is lower using SCR in place of long course schedules, in order
to treat a larger number of patients and to reduce patients’ waiting lists. In addition, our data
support the opportunity to set SCR into a chemoradiation approach for locally advanced rec-
tal cancer: induction or “waiting period” chemotherapy could increase the rate of tumor
regression.
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